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Background: In response to rapid global spread of the newly emerged coronavirus
disease 2019 (COVID-19), universities transitioned to online learning and telework to
decrease risks of inter-person contact. To help administrators respond to the COVID-19
pandemic and better understand its impacts, we surveyed SARS-CoV-2 seroprevalence
among NOVA University employees and assessed community mental health.
Methods: Data were collected from voluntary participants at six NOVA University
locations, in the Lisbon metropolitan area, from June 15–30, 2020. All subjects
provided written informed consent. Of 1,627 recruited participants (mean age 42.0
± 12.3 years), 1,624 were tested. Prior to blood collection, participants completed
a questionnaire that assessed: COVID-19 symptoms during the previous 14 days,
chronic non-communicable diseases, chronic medication, anxiety, and depression
symptoms. SARS-CoV-2 serology tests were then performed, and results communicated
approximately 4 days after blood draw. Participants with positive serology tests were
contacted to assess COVID-19 symptoms since February.
Results: Estimated prevalence of SARS-CoV-2 IgG antibodies was 3.1% (n = 50), of
which 43.5% reported symptoms in the previous 4 months. The Medical School had
the highest seroprevalence (6.2%). Participants reported having at least one chronic
disease (63.7%), depression-like symptoms (2.1%), and anxiety symptoms (8.1%).
Rates of depression and anxiety symptoms were significantly higher in women, with
sleep hours and occasional alcohol consumption negatively associated with depression.
Male gender, older age, and sleep hours negatively associated with anxiety symptoms.
School of employment and presence of comorbidities positively associated with anxiety.
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Conclusion: By measuring seroprevalence of SARS-CoV-2 antibodies among NOVA
employees and assessing subjects’ mental health, we aim to help administrators
at European public universities in urban areas, such as Lisbon, Portugal, better
understand the needs of their communities. This study resulted in implementation
of a stricter contingency plan in the Medical School, while other schools continued
to follow Government mitigation guidelines. These findings may also guide the
development of tailored strategies to ensure physical and mental health of the academic
community during this pandemic crisis. We conclude that, together with COVID-19
contingency plans, psychological support services and facilities to help people effectively
face pandemic-associated challenges and minimise anxiety and depression should
be implemented.
Keywords: coronavirus, SARS-CoV-2, serology testing, adaptation to COVID-19, public health, academic
environment, mental health
INTRODUCTION
In December of 2019, a new human disease caused by the
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
2) was identified in Wuhan, China (1). Since then, this disease,
known as coronavirus disease 2019 (COVID-19), has rapidly
spread, causing a worldwide pandemic, with over 115 million
infections and 2.5 million deaths. Portugal has reported over
800,000 infections and 16,000 deaths (2). In an attempt to
control rapid spread of the virus, governments around the world
took unprecedented steps—issuing shelter-in-place orders and
closing all non-essential businesses, including institutions of
higher education (3). For example, at the start of this pandemic,
beginning in early March 2020, Portugal imposed a national
lockdown, with people only resuming in-person work at the
end of May 2020. Accordingly, the COVID-19 outbreak and its
rapid global spread affected society on multiple levels, including
its educational systems. In particular, the rapid emergence and
spread of this disease necessitated a quick transition to online
learning and telework to minimise the risk of inter-personal
contact and subsequent COVID-19 infection (4, 5).
Due to the variable range of clinical presentations associated
with COVID-19, in some cases including absence of any
infection-related symptoms, disease incidence at higher
education institutions is difficult to assess. Although great focus
has been placed on understanding and minimising the risks of
COVID-19 for students (6–8), only limited research efforts have
focused on understanding and addressing the needs of university
employees. The COVID-19 pandemic has put significant
stress on these individuals, many of whom are worried about
the risk of being infected in the workplace and feeling both
increased financial pressure and insecurity about the future
(6, 9). Additionally, efforts to follow World Health Organization
directives to ensure health and safety of the academic community
have created significant organisational demands (10, 11) that
likely imposed an increased burden on university employees.
Researchers and professors may also feel heightened concerns
regarding the quality of their research and educational services,
as abrupt changes were made without sufficient preparation.
The unprecedented home lockdown experience also led to
several reports of increased anxiety and depression symptoms
(12, 13) and a subsequent increase in psychiatric medication
(14). Although, the impact of lockdown on mental health of
university employees is largely unknown, understanding this will
be critical for facing the myriad academic challenges generated
by the COVID-19 pandemic.
To assess the direct risk of SARS-CoV-2 infection faced by
university employees, we aimed to measure exposure to this virus
among NOVA faculty and staff. Moreover, to better understand
indirect pandemic-associated risks to employee health, we sought
to measure the mental health of professors, researchers, and staff
members during the process of adapting to COVID-19 measures
and preparing for the following school year. To achieve these
goals, we surveyed NOVA employees and assessed: (1) prevalence
of antibodies against SARS-CoV-2; (2) general health, including
the prevalence of diagnosed chronic diseases, depression, and
anxiety symptoms; and (3) specific factors associated with these
symptoms. Through this study, we aim to better understand
the comprehensive health risks faced by faculty and staff at a
university in a European capital highly affected by COVID-19.
MATERIALS AND METHODS
Setting
NOVA University includes nine independent schools, plus
the Rectory and Social Services, located in different sites
across the greater Lisbon metropolitan area. The individual
sites are as follows: Sciences and Technology School (FCT),
Social and Human Sciences (FCSH), School of Business and
Economics (SBE), Medical School (NMS), School of Law
(FD), Information Management School (IMS), Hygiene and
Tropical Medicine Institute (IHMT), National Public Health
School (ENSP), Chemical and Biological Technology Institute
(ITQB), the Rectory (RUNL), and Social Services (SAS). As
of December 31, 2019, NOVA employed a total of 3,308
workers, including 2,363 Professors/Researchers and 945 Non-
Professors/Non-Researchers (Table 1) (15).
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TABLE 1 | Characterisation of NOVA University workers.
Study population
2019 (n = 3,308)
Study sample
2020 (n = 1,624)
Sex
Female 1,829 (55%) 1,072 (66.0%)
Male 1,479 (45%) 552 (34.0%)
Age Group
<30 241 (8%) 296 (18.3%)
(30, 39) 719 (22%) 438 (27.1%)
(40, 49) 997 (30%) 413 (25.6%)
(50, 59) 841 (25%) 309 (19.1%)
≥60 510 (15%) 160 (9.9%)
Faculty/Institute
National Public Health School 67 (2%) 40 (2.6%)
Medical School 801 (24%) 240 (15.0%)
Social and Human Sciences School 620 (19%) 197 (12.3%)
Sciences and Technology School 753 (23%) 447 (28.0%)
Law School 69 (2%) 31 (1.9%)
Hygiene and Tropical Medicine
Institute
109 (3%) 46 (2.9%)
Chemical and Biological Technology
Institute
195 (6%) 289 (18.1%)#
Rectorate 172 (5%) 113 (7.1%)
Business and Economics School 438 (13%) 195 (12.2%)
Information and Management School 84 (3%) –
Occupational group
Professors/Researchers 2,363 (70%) 1,272 (81.6%)
Non-Professors/Non-Researchers 945 (30%) 287 (18.4%)
#Chemical and Biological Technology Institute (n= 225)+ Experimental and technological
Biology Institute (IBET) (n = 67).
Sample size is not constant due to missing values in: Age group (n = 1,616),
Faculty/Institute (n = 1,598), and Occupational group (n = 1,559).
Recruitment
In this observational cross-sectional study, the target
population consisted of employees—professors, researchers,
and administrative and operational staff—of the nine schools
within NOVA University, plus those in the RUNL and SAS.
The serosurvey was performed from June 15–30, 2020, by
a multidisciplinary team composed of doctors, nurses, and
research assistants at six locations: the RUNL, NMS, FCT,
ITQB, IBET, IHMT, and SBE. Recruitment began with an online
invitation from each school’s communications department
(n= 3,308), wherein an email for registry was made available.
Registration was voluntary and only required the candidate’s
name, email, and/or phone number. Only the research team had
access to participants registration to ensure that NOVA worker
privacy was protected in their organisational environment.
Along with the invitation email and registration form, we sent
two written informed consent forms: one for the serological
test and collection of epidemiological and clinical information
and another for blood sample storage at NOVA’s Biobank and
use in future research. Included in the email was also a link to
the epidemiological and clinical questionnaire. For underaged
participants, written informed consent to participate in this
study was provided by the participant’s legal guardian/next of
kin. Participants were given the opportunity to select the location
(one of the six available surveying sites) and time (between June
15–30) of the serological testing and epidemiological study. A
total of 1,627 workers participated in the study, and 1,624 were
tested (Figure 1). For information regarding the number of days
spent on each location and the number of participants tested per
day, please see Supplementary Material section file.
Procedure
At the serological testing site, participants had their temperature
taken and were asked if in the previous 14 days, they had
experienced any of the following symptoms: cough, fever, lack of
smell or taste. If one of these was reported, the subject was invited
to undergo a diagnostic reverse transcription (RT)-PCR test, free
of charge. Research assistants then collected the epidemiological
questionnaire and informed consent forms, addressed any
questions related to the study and/or COVID-19, and directed
participants to the blood collection stations. Subjects who did not
bring a completed epidemiological questionnaire were provided
with the opportunity to fill it out onsite. When requested
by participants, research assistants present at the location
assisted with completion of the questionnaire and answered
any existing questions. After form collection/completion, nurses
obtained blood samples from each participant for both storage
and sampling, and these were later analysed at the Human
Immunobiology and Pathogenesis Laboratory at the NOVANMS
Centre for the Study of Chronic Diseases (CEDOC). Following
the blood draw, participants were informed that their serological
test results would be provided in∼4 days.
Once the serological test results were known, participants
with positive serology were contacted by phone and invited to
answer a questionnaire containing questions related to COVID-
19. These included the following: “Since February of 2020, have
you had one of these symptoms—presence of cough, fever,
sore throat, lack of smell, lack of taste, headaches, body aches,
shortness of breath (yes/no)? If yes, indicate the date of first
symptoms. Since February of 2020, have you had contact with
someone diagnosed or suspected of having COVID-19 (yes/no)?
If yes, indicate the date. Since February, have you been travelling
abroad (yes/no)? If yes, indicate the date of travel and country.”
This study protocol was submitted and approved by the
NOVA NMS Ethics Committee, with all experiments and
laboratory analysis following the provisions of the Declaration
of Helsinki and the Good Clinical Practise guidelines of the
International Conference on Harmonisation.
Measures
The self-administered epidemiological questionnaire was
designed to assess the presence of COVID-19 symptoms, the
presence of chronic non-communicable diseases, the presence
of depression and anxiety symptoms, and lifestyle habits.
Specifically, the questionnaire was composed of questions
regarding sociodemographic information (e.g., age, sex, school,
level of education, job/position); anthropometric data (e.g.,
self-reported weight and height); COVID-19 symptoms in the
previous 14 days (e.g., “Have you had one of these symptoms
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FIGURE 1 | Flowchart of study design to measure SARS-CoV-2 seroprevalence and mental health among NOVA University employees.
in the last 14 days: presence of cough, fever, sore throat, lack of
smell, lack of taste, headaches, body aches, shortness of breath
(yes/no)?”); presence of chronic non-communicable diseases
(e.g., “Did any doctor tell you that you suffered from any of
the following chronic diseases: high cholesterol levels, high
blood pressure, allergy, gastrointestinal disease, mental disease,
cardiac disease, diabetes, pulmonary disease, hyperuricemia,
neoplastic disease, neurologic disease, urinary, rheumatic disease
(yes/no)?”); lifestyle characteristics, including sleep hours (e.g.,
“How many hours do you sleep a day (on average)?”), alcohol
intake (e.g., daily/occasionally/never), smoking habits (e.g.,
daily/occasionally/in the past/never); and chronic medication
(e.g., “What medication do you take every day?”).
To assess the presence of anxiety and depression symptoms,
we used the Hospital Anxiety and Depression Scale (HADS) (16),
which has been validated for the Portuguese population (17). This
instrument is composed of 14 questions that are rated on a four-
point scale: 0 (not present) to 3 (significant symptoms). Anxiety
and depression are assessed as separate components with seven
items each. The questionnaire can be easily self-administered
in ∼2–5min, showing good performance for inpatient and
outpatient scenarios, as well as against other scales and clinical
populations (18, 19). A score for each component was built by
summation of the appropriate items, based on the participants’
answers. Participants with scores ≥11 were classified as having
anxiety and depression symptoms, which indicates “probable
presence of the mood disorder,” as defined by Snaith (20). It is
important to note, however, that are goal was not to diagnose
depression or anxiety. Rather, our main aim was to assess the
presence of depression and anxiety symptoms that could be
present in the specific context of adaptation to the pandemic.
Laboratory Procedures for Serological
Testing
Blood samples were carefully transported and stored at the
NOVA Biobank, where the serum was collected by centrifugation
at 1,000 x g for 10min. Plasma samples were aliquoted and
stored in a Biobank freezer at −80◦C. For subsequent analysis,
the samples were thermally inactivated at 56◦C for 60 min (21).
Serological tests were performed as described previously (21),
within the scope of the Serology4COVID Consortium, which
brings together the NMS CEDOC, the ITQB, and the IBET at
NOVA, as well as the Gulbenkian Institute of Science (IGC),
and the Institute of Molecular Medicine (IMM) (22). Using a
modified enzyme-linked immunosorbent assay (ELISA) (21) that
is based on a published protocol (23), the seropositivity cut-off
point for IgG antibodies was set at 0.3987, with receiver operating
characteristic (ROC) curve analysis determining a sensitivity of
94.74% [CI95% (73.97, 99.87)] and a specificity of 99.53% [CI95%
(97.41, 99.99)] (21).
Statistical Analysis
A descriptive analysis was performed, the results of which
are presented as absolute frequencies, and prevalence estimates
for IgG antibodies were computed as proportions. Participants
with positive vs. negative serology results were compared, and
prevalence estimates were computed for each predictor, including
sex, age group, academic degree, faculty, body mass index
(BMI), occupational group, smoking, alcohol consumption,
and presence of chronic non-communicable comorbidities. The
estimated prevalence of anxiety or depression symptoms was
measured and compared between the two groups, and this was
cross tabulated with sex, age group, academic degree, faculty,
BMI, occupational group, smoking, alcohol consumption, and
chronic non-communicable comorbidities.
Logistic regression models were fit to evaluate the association
between presence of anxiety or depression symptoms and
possible determinants. We also performed univariate analysis to
test the following independent variables: demographic (e.g., sex,
age group, school), lifestyles (e.g., tobacco, alcohol consumption,
sleep hours), BMI, and comorbidities. The resulting variables
with p < 0.2 were included in the multivariate models to
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assess the differences between individuals with and without
depression or anxiety symptoms. The forward selection method
was used to construct the multivariate logistic models, and
possible confounding variables, such as sex and age group, were
forced to remain in the model.
Significance was set at p < 0.05. Descriptive analysis,
calculation of summary statistics, and statistical tests (Fisher, Chi-
Squared) were performed using STATA IC v.16.1 (24). Regression
models and graphics were generated using R Software (25).
RESULTS
A total of 1,627 subjects with a mean age of 42.0 ± 12.3 years
were recruited, of which 1,624 were tested for the presence
of IgG antibodies to SARS-CoV-2 (Figure 1). Response rate to
the invitation email was of 49.2% (n = 1,627/3,308). Sample
distribution is close to that of the study population with only
minor variations in some categories likely due to differences
from 2019 to 2020 (Table 1). Response rate to the questionnaire
was over 99%, with only eight participants refusing to answer
the questionnaire. Sample sizes for each variable response are
presented, varying slightly due to non-responded questions.
Logistic regression models were build using complete cases for
all variables.
Seroprevalence Against SARS-CoV-2
Among Employees of NOVA University
The estimated prevalence of IgG antibodies to SARS-CoV-2
among NOVA employees was found to be 3.1% (n = 50)
(Table 2). When stratifying positive cases per school, we found
that the NMS had the highest seroprevalence of IgG antibodies
(6.2%), compared to the other schools. Conversely, a much lower
seroprevalence was detected at the RUNL (0.9%), which had only
one case (Table 3).
Those with positive serology had similar characteristics to
participants with a negative result, being mostly women (68.0 vs.
65.9%, respectively) and with ages between 17 and 66 years (mean
age of 39.3 ± 11.95 vs. 42.0 ± 12.28 years, respectively). Twenty
participants (43.5%) with a positive result reported having at
least one symptom suggestive of COVID-19, and 10.9% reported
contact with diagnosed patients between February and June of
2020. In that same period, 12 participants with positive serology
travelled abroad (26.1%), with Spain and England being the most
frequent destinations.
Mental Health and Comorbidities of NOVA
University Employees During the COVID-19
Pandemic
A total of 63.7% of participants reported having at least
one chronic non-communicable disease, with 39.7% taking
medication for at least one chronic condition (Table 2). Allergies
were the most common chronic condition (35.5%), followed by
high cholesterol levels (16.6%).
The overall prevalence of depression symptoms was
2.1%, while that of anxiety symptoms was 8.1%, both
significantly affecting women more than men (depression:
TABLE 2 | Sociodemographic and health-related characterisation of NOVA







Sex n =1,624 n = 1,574 n = 50
Female 1,072 (66.0%) 1,038 (65.9%) 34 (68.0%)
Male 552 (34.0%) 536 (34.1%) 16 (32.0%)
Age Group n = 1,616 n = 1,566 n = 50
<30 296 (18.3%) 285 (18.2%) 11 (22.0%)
(30, 39) 438 (27.1%) 423 (27.0%) 15 (30.0%)
(40, 49) 413 (25.6%) 401 (25.6%) 12 (24.0%)
(50, 59) 309 (19.1%) 300 (19.2%) 9 (18.0%)
≥60 160 (9.9%) 157 (10.0%) 3 (6.0%)
Academic degree n = 1,557 n = 1,511 n = 46
PhD 633 (40.7%) 614 (40.6%) 19 (41.3%)
MSc 380 (24.4%) 368 (24.4%) 12 (26.1%)
BD 343 (22.0%) 333 (22.0%) 10 (21.7%)
Secondary School 131 (8.4%) 130 (8.6%) 1 (2.2%)
High School 43 (2.8%) 39 (2.6%) 4 (8.7%)
Complete Primary school 25 (1.6%) 25 (1.6%) –
Primary School 2 (0.1%) 2 (0.1%) –
Faculty/Institute n =1,598 n = 1,551 n = 47
ENSP 40 (2.6%) 40 (2.6%) –
NMS 240 (15.0%) 225 (14.5%) 15 (31.9%)
FCSH 197 (12.3%) 193 (12.4%) 4 (8.5%)
FCT 447 (28.0%) 438 (28.2%) 9 (19.2%)
FD 31 (1.9%) 30 (1.9%) 1 (2.1%)
IHMT 46 (2.9%) 44 (2.8%) 2 (4.3%)
ITQB/IBET 289 (18.1%) 280 (18.1%) 9 (19.1%)
RUNL 113 (7.1%) 112 (7.2%) 1 (2.1%)
SBE 195 (12.2%) 189 (12.2%) 6 (12.8%)
Body Mass Index (kg/m2) n = 1,583 n = 1,535 n = 48
Underweight (<18.5) 44 (2.8%) 42 (2.7%) 2 (4.2%)
Normal (18.5–24.9) 910 (57.5%) 881 (57.4%) 29 (60.4%)
Overweight (25–29.9) 475 (10.0%) 460 (30.0%) 15 (31.3%)
Obese (≥30) 154 (9.7%) 152 (9.9%) 2 (4.2%)
Occupational group n = 1,559 n = 1,514 n = 45
Armed Forces 1 (0.1%) 1 (0.1%) –
Executives/Directors/Managers 42 (2.7%) 42 (2.8%) –
Scientific and Intellectual
Areas
1,272 (81.6%) 1,235 (81.6%) 37 (82.2%)
Middle level 73 (4.7%) 69 (4.6%) 4 (8.9%)
Administrative 98 (6.3%) 97 (6.4%) 1 (2.2%)
Personal Services 20 (1.3%) 20 (1.3%) –
Agriculture/Fishing – – –
Industry/Construction 8 (0.5%) 8 (0.5%) –
Machine operators – – –
Non-qualified workers 45 (2.9%) 42 (2.8%) 3 (6.7%)
Smoking n = 1,608 n = 1,558 n = 50
Never 907 (56.4%) 882 (56.6%) 25 (50.0%)
Daily 214 (13.3%) 210 (13.5%) 4 (8.0%)
Occasionally 101 (6.3%) 95 (6.1%) 6 (12.0%)
In the past 380 (23.6%) 365 (23.4%) 15 (30.0%)
(Continued)
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DK/DA 6 (0.4%) 6 (0.4%) –
Alcohol n = 1,592 n = 1,543 n = 49
Never 198 (12.4%) 192 (12.4%) 6 (12.2%)
Daily 130 (8.2%) 124 (8.0%) 6 (12.2%)
Occasionally 1,255 (78.8%) 1,218 (78.9%) 37 (75.5%)
DK/DA 9 (0.6%) 9 (0.6%) –
Comorbidities n = 1,624 n = 1,574 n = 50
No 590 (36.3%) 568 (36.1%) 22 (44.0%)
Yes 1,034 (63.7%) 1,006 (63.9%) 28 (56.0%)
Presence of Chronic Diseases*
Hypertension 190 (11.8%) 187 (11.9%) 3 (6.0%)
Diabetes 32 (2.0%) 31 (2.0%) 1 (2.0%)
Cholesterol 266 (16.6%) 258 (16.6%) 8 (16.0%)
Pulmonary 58 (3.6%) 57 (3.7%) 1 (2.0%)
Cardiac 101 (6.3%) 99 (6.3%) 2 (4.0%)
Thrombose 8 (0.5%) 8 (0.5%) –
Digestive 246 (15.3%) 238 (15.3%) 8 (16.0%)
Neurological 180 (11.2%) 175 (11.2%) 5 (10.2%)
Allergies 571 (35.5%) 556 (35.7%) 15 (30.0%)
Oncological 44 (2.8%) 43 (2.8%) 1 (2.0%)
Hyperuricemia 25 (1.6%) 23 (1.5%) 2 (4.0%)
Urinary 74 (4.8%) 74 (4.8%) –
Rheumatic 82 (5.3%) 80 (5.4%) 2 (4.1%)
Chronic medication n = 1,616 n = 1,566 n = 50
No 975 (60.3%) 940 (60.0%) 35 (70.0%)
Yes 641 (39.7%) 626 (40.0%) 15 (30.0%)
Presence of Anxiety 121 (8.1%) 114 (7.8%) 7 (16.3%)
Presence of Depression 32 (2.1%) 30 (2.1%) 2 (4.6%)
*Sample size is not constant due to missing values in: Hypertension (n = 1,611), Diabetes
(n = 1,606), Cholesterol (n = 1,605), Pulmonary (n = 1,612), Cardiac (n = 1,612),
Thrombose (n = 1,611), Digestive (n = 1,606), Neurological (n = 1,608), Allergies (n
= 1,609), Oncological (n = 1,575), Hyperuricemia (n = 1,585), Urinary (n = 1,583),
Rheumatic (n = 1,545), Presence of Anxiety (n = 1,500), Presence of Depression (n
= 1,507).
Negative SARS-CoV-2 serology: Hypertension (n = 1,561), Diabetes (n = 1,556),
Cholesterol (n = 1,555), Pulmonary (n = 1,562), Cardiac (n = 1,562), Thrombose (n =
1,561), Digestive (n = 1,556), Neurological (n = 1,559), Allergies (n = 1,559), Oncological
(n = 1,525), Hyperuricemia (n = 1,535), Urinary (n = 1,533), Rheumatic (n = 1,496),
Presence of Anxiety (n = 1,457), Presence of Depression (n = 1,463).
Positive SARS-CoV-2 serology: Neurological (n = 49), Rheumatic (n = 49), Presence of
Anxiety (n = 43), Presence of Depression (n = 44).
DK/DA, Didn’t know/ Didn’t answer.
84.4 vs. 15.6%, respectively, Fisher’s exact p = 0.024;
anxiety: 87.6 vs. 12.4%, respectively, Fisher’s exact p =
0.000) (Table 4). Alcohol consumption was also negatively
associated with the presence of depression symptomatology
(Pearson Chi2 = 8.267, p = 0.041), with those reporting
occasional and daily consumption levels having lower
depression frequencies relative to participants who did not
drink (Figure 2).
NOVA’s Law School (FD) had the highest prevalence
of anxiety symptoms (24.1%) (Figure 3), with all groups







Total n = 3,308 n = 1,624
(49.2%)
n = 50 (3.1%)
Faculty/Institute n = 1,598 n = 47
National Public
Health School
67 40 (59.7%) –
Medical School 801 240 (30.0%) 15 (6.2%)
Social and Human
Sciences School
620 197 (31.8%) 4 (2.0%)
Sciences and
Technology School
753 447 (59.4%) 9 (2.0%)
Law School 69 31 (44.9%) 1 (3.2%)
Hygiene and Tropical
Medicine Institute







Rectorate 172 113 (65.7%) 1 (0.9%)
Business and
Economics School




#Chemical and Biological Technology Institute (n= 225)+ Experimental and technological
Biology Institute (IBET) (n = 67).
differing significantly (Pearson Chi2 = 19.605, p = 0.012;
Table 4). Further, although the differences were not statistically
significant, we noted a higher prevalence of depression
(4.6%) and anxiety (16.3%) among participants with positive
serology, relative to those who were negative (2.1 and
7.8%, respectively).
Logistic regression analysis to identify factors associated
with depression symptoms revealed statistically significant
negative associations between depression symptoms and an
increase in daily sleep hours (OR = 0.464, p < 0.001)
and between depression symptoms and occasional alcohol
drinkers in comparison to non-drinkers (OR = 0.405, p =
0.045) (Table 5). In particular, a mean increase in 1 h of
sleep per day was found to decrease the odds of depression
symptomatology by 53.6% (1–0.464). The odds of depression
symptoms decreased by 59.5% for occasional alcohol drinkers
compared to those who never drink alcohol. The odds of
depression symptoms were 2.7 times higher for those with
comorbidities, relative to those without comorbidities. We
further note that although sex and age groups were not
significantly associated with depression when adjusting for the
remaining predictors, we considered them important and kept
them in the model.
The presence of anxiety symptoms showed a significant
negative association with being male (OR = 0.246, p < 0.001),
being in older age groups compared to the <30 years-old group,
sleeping more hours (OR = 0.452, p < 0.001), and belonging
to NMS (OR = 0.410, p = 0.04) vs. the FCT. Conversely, the
presence of comorbidities (OR= 2.888, p< 0.001) and belonging
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TABLE 4 | Sociodemographic and health-related characterisation of NOVA









Sex n = 1,627 n = 32 n = 121
Female 1,074 (66.0%) 27 (84.4%) 106 (87.6%)
Male 553 (34.0%) 5 (15.6%) 15 (12.4%)
Age Group n = 1,619 n = 32 n = 121
<30 297 (18.3%) 3 (9.4%) 28 (23.1%)
(30, 39) 438 (27.1%) 7 (21.9%) 30 (24.8%)
(40, 49) 414 (25.6%) 10 (31.3%) 36 (30.0%)
(50, 59) 310 (19.1%) 10 (31.3%) 20 (16.5%)
≥60 160 (9.9%) 2 (6.2%) 7 (5.8%)
Academic degree n = 1,560 n = 31 n = 120
PhD 634 (40.6%) 13 (42.0%) 47 (39.2%)
MSc 381 (24.4%) 9 (29.0%) 29 (24.2%)
BD 344 (22.1%) 4 (12.9%) 30 (25.0%)
Secondary School 131 (8.4%) 5 (16.1%) 20 (8.3%)
High School 43 (2.7%) – 4 (3.3%)
Complete primary school 25 (1.6%) – –
Primary School 2 (0.1%) – –
Faculty/Institute n = 1,601 n = 32 n = 117
ENSP 40 (2.5%) 1 (3.1%) 3 (2.6%)
NMS 240 (15.0%) – 8 (6.8%)
FCSH 197 (12.3%) 6 (18.8%) 19 (16.2%)
FCT 448 (27.9%) 13 (40.6%) 32 (27.4%)
FD 31 (1.9%) – 7 (6.0%)
IHMT 46 (2.9%) 2 (6.2%) 3 (2.6%)
ITQB/IBET 290 (18.1%) 4 (12.5%) 25 (21.4%)
RUNL 114 (7.1%) 1 (3.1%) 9 (7.7%)
SBE 195 (12.2%) 5 (15.6%) 11 (9.4%)
Body Mass Index (kg/m2) n = 1,586 n = 31 n = 118
Underweight (<18.5) 44 (2.8%) 1 (3.2%) 4 (3.4%)
Normal (18.5–24.9) 912 (57.5%) 16 (51.6%) 69 (58.5%)
Overweight (25–29.9) 475 (30.0%) 8 (25.8%) 28 (23.7%)
Obese (≥30) 155 (9.8%) 6 (19.4%) 17 (14.4%)
Occupational group n = 1,562 n = 30 n = 118
Armed Forces 1 (0.1%) – –
Executives/Directors/Managers 42 (2.7%) – 5 (4.2%)
Scientific and Intellectual
Areas
1,275 (81.6%) 21 (70.0%) 84 (71.2%)
Middle level 73 (4.7%) 2 (6.7%) 5 (4.2%)
Administrative 98 (6.3%) 4 (13.3%) 7 (5.9%)
Personal Services 20 (1.3%) – 1 (0.9%)
Agriculture/Fishing – – –
Industry/Construction 8 (0.5%) – 3 (2.5%)
Machine operators – – –
Non-qualified workers 45 (2.9%) 3 (10.0%) 13 (11.0%)
Smoking n = 1,611 n = 32 n = 120
Never 910 (56.5%) 14 (43.8%) 55 (45.8%)
Daily 214 (13.3%) 7 (21.9%) 21 (17.5%)
Occasionally 101 (6.3%) 3 (0.4%) 11 (9.2%)
(Continued)









In the past 380 (23.6%) 8 (25.0%) 32 (26.7%)
DK/DA 6 (0.4%) – 1 (0.8%)
Alcohol n = 1,595 n = 32 n = 121
Never 198 (12.4%) 9 (28.1%) 19 (15.7%)
Daily 131 (8.2%) 1 (3.1%) 8 (6.6%)
Occasionally 1,257 (78.8%) 22 (68.8%) 94 (77.7%)
DK/DA 9 (0.6%) – –
Comorbidities n = 1,627 n = 32 n = 121
No 591 (36.3%) 4 (12.5%) 25 (20.7%)
Yes 1,036 (63.7%) 28 (87.5%) 96 (79.3%)
Presence of Chronic Diseases*
Hypertension 191 (11.8%) 5 (15.6%) 15 (12.4%)
Diabetes 32 (2.0%) – 4 (3.3%)
Cholesterol 267 (16.6%) 9 (28.1%) 25 (20.7%)
Pulmonary 58 (3.6%) 1 (3.1%) 3 (2.5%)
Cardiac 101 (6.3%) 9 (28.1%) 16 (12.2%)
Thrombose 8 (0.5%) 1 (3.2%) –
Digestive 247 (15.4%) 10 (31.3%) 31 (25.8%)
Neurological 180 (11.2%) 7 (21.9%) 29 (24.0%)
Allergies 572 (35.5%) 16 (50.0%) 59 (48.8%)
Oncological 44 (2.8%) 3 (9.7%) 4 (3.4%)
Hyperuricemia 25 (1.6%) 2 (6.3%) 4 (3.3%)
Urinary 74 (4.7%) 3 (9.4%) 6 (5.0%)
Rheumatic 82 (5.3%) 5 (16.7%) 13 (11.3%)
*Sample size is not constant due to missing values in: Hypertension (n = 1,614), Diabetes
(n = 1,609), Cholesterol (n = 1,608), Pulmonary (n = 1,615), Cardiac (n = 1,615),
Thrombose (n = 1,614), Digestive (n = 1,609), Neurological (n = 1,611), Allergies (n
= 1,612), Oncological (n = 1,578), Hyperuricemia (n = 1,588), Urinary (n = 1,586),
Rheumatic (n = 1,548).
Participants with depression symptoms: Diabetes (n = 31), Thrombose (n = 31),
Oncological (n = 31), Rheumatic (n = 30).
Participants with anxiety symptoms: Diabetes (n = 120), Thrombose (n = 120), Digestive
(n = 120), Oncological (n = 119), Hyperuricemia (n = 120), Urinary (n = 120), Rheumatic
(n = 115).
DK/DA, Didn’t know/ Didn’t answer.
to the FD (OR = 6.275, p < 0.001) vs. the FCT (Table 6) were
positively associated with anxiety symptoms.
DISCUSSION
The low prevalence of SARS-CoV-2 antibodies detected in this
study (3.1%) is consistent with other reports (26, 27). Our
results also align with the 2.9% estimated prevalence reported
from a serological study of the Portuguese population performed
in July of 2020 (28), indicating that NOVA employees were
not at a higher risk of contracting the disease. However, our
prevalence rate is somewhat higher than that detected by the
COVID-19 National Serological Panel (1.9%) in September
2020 (29). The difference found in the prevalence of SARS-
CoV-2 antibodies between our study’s and the COVID-19
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FIGURE 2 | Prevalence of depression symptoms per alcohol consumption levels (n = 32).
FIGURE 3 | Prevalence of anxiety symptoms based on the number of individuals per organic unit (n = 117).
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TABLE 5 | Logistic regression analysis to identify factors associated with the
presence of depression symptoms in NOVA employees.
Depression β OR 95% CI z p
Sex
Female (ref) – – – – –
Male −0.753 0.471 (0.154, 1.194) −1.469 0.142
Age group
<30 (ref) – – – – –
(30, 39) 0.256 1.292 (0.332, 6.236) 0.356 0.722
(40, 49) 0.633 1.883 (0.553, 8.603) 0.937 0.349
(50, 59) 0.615 1.850 (0.503, 8.767) 0.875 0.382
≥60 −1.116 0.328 (0.015, 2.617) −0.941 0.347
Sleep hours −0.768 0.464 (0.311, 0.691) −3.792 <0.001*
Alcohol
Never (ref) – – – – –
Daily −1.448 0.235 (0.012, 1.414) −1.320 0.187
Occasionally −0.905 0.405 (0.172, 1.034) −2.001 0.045*
Comorbidities 1.009 2.743 (1.018, 9.554) 1.814 0.070
(n = 1,345) AIC: 259.29
OR, Odds Ratio; β, Regression coefficients; 95% CI, 95% Confidence intervals; z, z-test
statistics; p, p-values; AIC, Akaike Information Criteria.
Regression coefficients, odds ratios (ORs), 95% confidence intervals (CIs), z-test values,
and Wald test p-values of the model (symptoms suggestive of depression vs. no
symptoms suggestive of depression) are shown.
National Serological Panel one could potentially be explained
by the subsequent: government-enforced national lockdown,
social distancing, and the fast transition to distance learning and
telework. Nevertheless, it is worth noting that the low prevalence
found in this study is also indicative that, at the time of testing,
there was no active community transmission of COVID-19
within NOVA University.
Among the surveyed schools, the Medical School (NMS) had
the highest seroprevalence of IgG anti-SARS-CoV-2 antibodies
(6.2%), followed by the Tropical Medicine Institute (IHMT;
4.3%). This result might be due to the fact that workers in
these schools were practising clinicians, who were not confined
and, thus, had a higher risk of being exposed to the virus.
The lower seroprevalence detected in other schools, with a
maximum of 3.2%, is more in line with national figures
(28). Similarly, a serological study at the University of Athens
reported higher seroprevalence in health science schools during
June/July of 2020, although this was not statistically significant
(30). These findings suggest that the massive reduction of in-
person academic activities effectively prevented the spread of
SARS-CoV-2, leading us to propose additional measures to
further minimise inter-person contacts. Our study informed
the NOVA University management structure of the need to
implement a stricter contingency plan in the NMS, while other
schools within the university continued to follow Government
mitigation guidelines.
In the United States, reopening of campuses was considered
safe and to have minimal impact on community spread if
positivity rates were under 5%, provided regular testing was
TABLE 6 | Logistic regression analysis to identify factors associated with the
presence of anxiety symptoms in NOVA employees.
Anxiety β OR 95% CI z p
Sex
Female (ref) – – – – –
Male −1.402 0.246 (0.129, 0.438) −4.519 <0.001*
Age group
<30 (ref) – – – – –
(30, 39) −0.673 0.510 (0.274, 0.949) −2.134 0.032*
(40, 49) −0.640 0.527 (0.281, 0.990) −1.999 0.046*
(50, 59) −1.092 0.336 (0.158, 0.691) −2.921 0.003*
≥60 −2.332 0.097 (0.022, 0.308) −3.555 <0.001*
Sleep hours −0.795 0.452 (0.353, 0.573) −6.467 <0.001*
Faculty/Institution
FCT (ref) – – – – –
ENSP −0.105 0.900 (0.138, 3.365) −0.135 0.892
NMS −0.891 0.410 (0.165, 0.922) −2.053 0.040*
FCSH 0.353 1.423 (0.707, 2.796) 1.012 0.312
FD 1.837 6.275 (2.104, 17.473) 3.439 <0.001*
IHMT −0.537 0.584 (0.087, 2.287) −0.674 0.500
ITQB/IBET 0.139 1.150 (0.610, 2.153) 0.435 0.663
RUNL 0.039 1.040 (0.413, 2.398) 0.089 0.929
SBE −0.411 0.663 (0.277, 1.458) −0.982 0.326
Comorbidities 1.061 2.888 (1.720, 5.084) 3.854 <0.001*
(n = 1,332) AIC: 645.88
OR, Odds Ratio; β, Regression coefficients; 95% CI, 95% Confidence intervals; z, z-test
statistics; p, p-values; AIC, Akaike Information Criteria.
Regression coefficients, odds ratios (ORs), 95% confidence intervals (CIs), z-test values,
and Wald test p-values of the model (symptoms suggestive of anxiety vs. no symptoms
suggestive of anxiety) are shown.
implemented to monitor infection rates (31). Universities could
reopen with regular testing and measures to prevent physical
contact. Such measures include arranging circuits to ensure
physical distancing and limiting campus class attendance by
employing blended classes (i.e., online plus in-person), combined
with standard good practises, such as mandatory mask usage,
regular disinfection of hands and surfaces, and temperature
measurements Other recommendedmeasures include publishing
daily or weekly metrics regarding safety protocols and the
number of cases and tests at the university, independent from
regional data, to understand differences between academic and
local communities (32). Such communication would also provide
valuable feedback to university personnel regarding the impact
of safety measures, which is expected to favour adherence to
contingency initiatives (33).
Our findings showed a positivity rate of 3.1% which allowed
us to recommend at NOVA University’s Governing Body a
safe campus reopening. Even though in our university most
infections took place outside the campus, a rigorous contingency
plan was developed to lower the risk of COVID-19 spread on
campus. We have participated in the development of NOVA
COVID-19 Contingency Plan and proposed measures such as
the progressive return to in-person work, massive testing of all
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university employees, enforcing indoor room occupancy limits;
defining circuits of entry, occupation, exit and circulation; and
implementing mandatory face mask usage when at NMS.
Based on our results, it was possible to define strategies
that would need to be developed, implemented, and adjusted
to prepare for the upcoming academic year (2020–2021) and
effectively prevent the spread of COVID-19 infection.
Our mental health assessment of the NOVA academic
community further revealed a relatively low prevalence of anxiety
and depression symptoms when compared with other studies
of the general population (34–36), and even in universities
before the pandemic (37, 38). Nevertheless, these rates were
not negligible, and we report a number of key findings.
The results revealed a high prevalence of moderate-to-severe
anxiety symptoms in the institution’s community. Following this
evidence, the Rectory was duly informed of the scenery found by
the present study. Accordingly, our team of researchers launched
an alert on the need to respond to the disturbing mental health
situation, having suggested creating a crisis office service. This
crisis office service would react as the first line to the urgent needs
of mental health, in a logic of psychological first aid, rooted in
a model of seven steps: T – triage; P – Protect; S – Stabilise;
I – Inform; E – Educate; C – Connect; HO - Help Organise,
and R – Refer (39, 40). In addition, it was also suggested the
creation of a mental health intervention office or decentralised
offices, in a structural and long-lasting service logic, including
public health and mental health professionals, to promote global
occupational health.
Although we found no significant differences between
prevalence of depression and anxiety in seropositive vs. negative
individuals, the presence of these symptoms may reflect a
general concern and fear related to the pandemic and pandemic-
associated constraints (41). However, further research is needed
to address the overall lack of knowledge relating to the impact
that this pandemic has had on mental health of university
personnel and to identify its effects on their well-being and
life satisfaction. In addition to pandemic-induced worry about
family, friends, and infected acquaintances, as well as uncertainty
and fear for the future, the COVID-19-related lockdowns have
created social isolation, which is an established risk factor for
psychological harm (42, 43). In their systematic review based
on 25 studies, Prati et al. found a small, yet significant, effect of
the COVID-19 lockdowns on mental health symptoms within
the general population, namely depression and anxiety, although
the authors cautiously note the high heterogeneity of effects (44).
Moreover, anxiety and depression have been reported to be more
frequent in women than in men due to biological differences, as
well as the lack of social attitudes, policies, and support systems
to promote equality (45). Among the participants that showed
anxiety symptoms, the majority were from the Law School (FD).
We believe that this may be due to the organisational culture,
management, or leadership differences, although we also note
that this school had the smallest sample size (n = 29), thus
showing greater variation.
Based on our logistic regression analysis, alcohol consumption
was significantly associated with lower risk of depression, male
gender and increased age were significantly associated with
decreased anxiety, and sleep hours were significantly associated
with lower risk of both depression and anxiety symptoms. In
contrast, the presence of comorbidities was positively associated
with anxiety. Other studies have described a J-shape association
between alcohol consumption and depression symptoms, i.e., a
lower risk of depression for light and moderate drinkers when
compared to extreme drinkers or non-drinkers (46, 47), even
when adjusted for past drinking (48). This negative association
with depression for occasional drinkers may be explained by
unmeasured social behaviour. That is, non-drinkers might be
reluctant to attend social gatherings that involve alcohol use,
and if limited social opportunities are, in fact, due to the
decision not to drink, this can lead to increased depression
and social anxiety (48). However, it is unclear whether this
was a factor here, given the increased distancing and general
decrease in social activities for both drinkers and non-drinkers
during the pandemic. Our results also align with some previously
reported risk factors for depression and anxiety symptoms, such
as female gender (49, 50) and comorbidities (51). Workload
has also been reported to be positively associated with the
presence of psychological disturbances, including anxiety and
depression (52, 53). Moreover, although anxiety and depression
symptoms were not present in any of the medical staff in our
sample, the majority of participants worked in scientific and
intellectual areas, limiting statistical power to infer occupational
group differences. Accordingly, our results highlight the need
for preventive intervention to support academic communities
and promote mental health, such as by creating mobile support
lines targeting the academic community (54). Overall, a major
strength of this study is that, unlike the national serological
study, we have obtained serological information to measure
SARS-CoV-2 exposure in an academic environment during
the first COVID-19 wave, and in conjunction, we further
provide a robust characterisation of the general mental health
of the study population. Study limitations include the fact
that our results were based on self-reports of diseases and
COVID-19 symptoms, and therefore, we cannot ensure that
participants paid sufficient attention to these questions, and
thus the veracity of their answers, due to daily life stresses and
time constraints.
CONCLUSION
This study aimed to estimate the seroprevalence of SARS-CoV-
2 antibodies and provide insight on the mental health status of
workers in an academic environment. Our findings contribute to
the general knowledge on prevalence of SARS-CoV-2 antibodies,
which we found to be close to the national estimated prevalence
for July (3.1 vs. 2.9%, respectively), indicating that NOVA
employees were not at higher risk of having COVID-19.
The results of this study allowed us to recommend at
NOVA University’s Governing Body a safe campus reopening
and prepare campus contingency policies to deal with the
pandemic and to implement reopening plans. Althoughwe found
a lower prevalence of anxiety and depression symptoms than
in other general population studies and even academic studies
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before the pandemic, these symptoms are frequent in academic
environments and are consistently higher in certain groups (e.g.,
women), suggesting that the development of strategies to prevent
mental illness and provide increased support to at-risk members
of the academic community should be a priority. NOVA rectory
was duly informed of the scenery found by the present study.
Accordingly, our team of researchers launched an alert on the
need to respond to the disturbing mental health situation, having
suggested creating a crisis office service.
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